Citations

Showing 10 of 108094 citations.

Elastin-like Polypeptide Hydrogels for Tunable, Sustained Local Chemotherapy in Malignant Glioma
Dragojevic, Sonja , Turner, Lindsay, Pal, Pallabi , Janorkar, Amol V. , Raucher, Dražen

Mayo Clinic

Pharmaceutics | September 28, 2022 | Volume: 14 | Issue: 10 | Pages: 2072

10.3390/pharmaceutics14102072 | PMID 36297507 Get It

Glioblastoma (GBM) is a primary brain tumor that carries a dismal prognosis, which is primarily attributed to tumor recurrence after surgery and resistance to chemotherapy. Since the tumor recurrence appears near the site of surgical resection, a concept of immediate and local application of chemotherapeutic after initial tumor removal could lead to improved treatment outcome. With the ultimate goal of developing a locally-applied, injectable drug delivery vehicle for GBM treatment, we created elastin-like polypeptide (ELP) hydrogels. The ELP hydrogels can be engineered to release anti-cancer drugs over an extended period. The purpose of this study was to evaluate the biomechanical properties of ELP hydrogels, to characterize their ability to release doxorubicin over time, and to investigate, in vitro, the anti-proliferative effect of Dox-laden ELP hydrogels on GBM. Here, we present microstructural differences, swelling ratio measurements, drug release characteristics, and in vitro effects of different ELP hydrogel compositions. We found that manipulation of the ELP–collagen ratio allows for tunable drug release, that the released drug is taken up by cells, and that incubation with a small volume of ELP-Dox hydrogel drastically reduced survival and proliferation of GBM cells in vitro. These results underscore the potential of ELP hydrogels as a local delivery strategy to improve prognosis for GBM patients after tumor resection.
Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
Desai, Sanjal H. , Mwangi, Raphael , Ng, Wern Lynn , King, Rebecca L. , Maurer, Matthew J. , Cerhan, James R. , Feldman, Andrew L. , Farooq, Umar , Mou, Eric , Thompson, Carrie A. , Nowakowski, Grzegorz S. , Wang, Yucai , Witzig, T.E. , Feldman, Andrew L , Maurer, Matthew , Cerhan, James R , Farooq, Umar , Desai, Sanjal , Mou, Eric , Habermann, Thomas M. , Wang, Yucai , Witzig, Thomas E.

Mayo Clinic

Blood Advances | September 28, 2022 | Volume: 6 | Issue: 24 | Pages: 6180-6186

10.1182/bloodadvances.2022007569 | PMID 36170803 Get It

Abstract An enhanced understanding of the molecular heterogeneity of diffuse large B-cell lymphoma (DLBCL) has opened the door to clinical trials evaluating novel agents with subtype-specific activity. It is an emerging question whether core needle biopsies (CNB) can adequately meet the increasing tissue requirements of these clinical trials. This can potentially lead to selective enrollment of patients who can undergo excisional biopsy (EB). It is also important to know whether patients who can undergo extensive diagnostic work up differ in their disease characteristics and outcomes from those who cannot. In this observational study, we describe the characteristics, outcomes, and adequacy of diagnostic tissue in patients with newly diagnosed DLBCL and primary mediastinal large B-cell lymphoma who underwent EB vs CNB. Of the 1061 patients, 532 (49.8%) underwent EB and 529 (50.1%) underwent CNB. A significantly higher proportion of patients with CNB had advanced stage disease, an international prognostic index of ≥3, and inadequate tissue for molecular analyses. Patients with CNB had significantly worse 5-year event-free survival (67.6% vs 56.9%; hazard ratio [HR], 0.76; confidence interval [CI]95, 0.6-0.9, P < .001) and 5-year overall survival (76.4% vs 69.2%; HR, 0.8; CI95, 0.6-0.9, P < .001). Thus, patients who underwent CNB have poor-risk features and inferior outcomes on frontline chemoimmunotherapy, are more likely to have inadequate tissue for molecular analyses, and might not meet the tissue requirements of biomarker-driven clinical trials. Thus, the increasing tissue requirements of biomarker-driven clinical trials may result in the exclusion of patients with high-risk DLBCL who need novel agents.
Cardiovascular Factors Associated with COVID-19 from an International Registry of Primarily Japanese Patients
Matsumori, Akira , Auda, Matthew E. , Bruno, Katelyn A. , Shapiro, Katie A., Kato, Toru , Nakamura, Toshihiro , Hasegawa, Koji, Saleh, Ahmed , Abd-Elrazek, Sherif , Negm, H., Karunawan, Niyata Hananta , Cooper, Leslie T. , Fairweather, DeLisa , Fairweather, DeLisa , Cooper, Leslie T , Bruno, Katelyn A

Mayo Clinic

Diagnostics | September 28, 2022 | Volume: 12 | Issue: 10 | Pages: 2350

10.3390/diagnostics12102350 | PMID 36292038 Get It

Aims: We developed an international registry to examine cardiovascular complications of COVID-19. Methods: A REDCap form was created in March 2020 at Mayo Clinic in collaboration with the International Society of Cardiomyopathy, Myocarditis and Heart Failure (ISCMF) and data were entered from April 2020 through April 2021. Results: Of the 696 patients in the COVID-19 Registry, 411 (59.2%) were male and 283 (40.8%) were female, with a sex ratio of 1.5:1 male to female. In total, 95.5% of the patients were from Japan. The average age was 52 years with 31.5% being >65 years of age. COVID-19 patients with a history of cardiovascular disease (CVD) had more pre-existing conditions including type II diabetes (p < 0.0001), cancer (p = 0.0003), obesity (p = 0.001), and kidney disease (p = 0.001). They also had a greater mortality of 10.1% compared to 1.7% in those without a history of CVD (p < 0.0001). The most common cardiovascular conditions in patients with a history of CVD were hypertension (33.7%), stroke (5.7%) and arrhythmias (5.1%). We found that troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP (NT-proBNP), C-reactive protein (CRP), IL-6 and lambda immunoglobulin free light chains (Ig FLC) were elevated above reference levels in patients with COVID-19. Myocarditis is known to occur mainly in adults under the age of 50, and when we examined biomarkers in patients that were ≤50 years of age and had no history of CVD we found that a majority of patients had elevated levels of troponin T (71.4%), IL-6 (59.5%), creatine kinase/CK-MB (57.1%), D-dimer (57.8%), kappa Ig FLC (75.0%), and lambda Ig FLC (71.4%) suggesting myocardial injury and possible myocarditis. Conclusions: We report the first findings to our knowledge of cardiovascular complications from COVID-19 in the first year of the pandemic in a predominantly Japanese population. Mortality was increased by a history of CVD and pre-existing conditions including type II diabetes, cancer, obesity, and kidney disease. Our findings indicate that even in cases where no abnormalities are found in ECG or ultrasound cardiography that myocardial damage may occur, and cardiovascular and inflammatory biomarkers may be useful for the diagnosis.
Postoperative Urinary Retention after Pediatric Orthopedic Surgery
Singleton, Ian M. , Burns, Jessica , Temkit, M’hamed , Belthur, Mohan V. , Sitzman, Thomas J.

Mayo Clinic

Children | September 28, 2022 | Volume: 9 | Issue: 10 | Pages: 1488

10.3390/children9101488 | PMID 36291424 Get It

Purpose: This study aims to describe the incidence of postoperative urinary retention among pediatric patients undergoing orthopedic surgery and identify risk factors. Methods: The Pediatric Health Information System was used to identify children aged 1–18 years who underwent orthopedic surgery. Collected from each patient’s record were demographic information, principal procedure during hospitalization, the presence of neurologic/neuromuscular conditions and other complex chronic medical conditions, the total postoperative length of stay, and the presence of postoperative urinary retention. Results: The overall incidence of postoperative urinary retention was 0.38%. Children with complex chronic neuromuscular conditions (OR 11.54 (95% CI 9.60–13.88), p = < 0.001) and complex chronic non-neuromuscular medical conditions (OR 5.07 (95% CI 4.11–6.25), p ≤ 0.001) had a substantially increased incidence of urinary retention. Surgeries on the spine (OR 3.98 (95% CI 3.28–4.82, p ≤ 0.001) and femur/hip (OR 3.63 (95% CI 3.03–4.36), p ≤ 0.001) were also associated with an increased incidence. Conclusions: Children with complex chronic neuromuscular conditions have a substantially increased risk of experiencing postoperative urinary retention. Complex chronic non-neuromuscular medical conditions and surgeries to the spine, hip, and femur also carry a notably increased risk.
Targeting Cellular Senescence for Age-Related Diseases: Path to Clinical Translation
Wyles, Saranya P. , Kirkland, James L. , Tchkonia, Tamara, Tchkonia, Tamar

Mayo Clinic

Plastic & Reconstructive Surgery | September 28, 2022 | Volume: 150 | Issue: No issue available | Pages: 20S-26S

10.1097/prs.0000000000009669 | PMID 36170432 Get It

Summary: Beyond the palliative reach of today’s medicines, medical therapies of tomorrow aim to treat the root cause of age-related diseases by targeting fundamental aging mechanisms. Pillars of aging include, among others, genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, dysregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. The unitary theory of fundamental aging processes posits that by targeting one fundamental aging process, it may be feasible to impact several or all others given its interdependence. Indeed, pathologic accumulation of senescent cells is implicated in chronic diseases and age-associated morbidities, suggesting that senescent cells are a good target for whole-body aging intervention. Preclinical studies using senolytics, agents that selectively eliminate senescent cells, and senomorphics, agents that inhibit production or release of senescence-associated secretory phenotype factors, show promise in several aging and disease preclinical models. Early clinical trials using a senolytic combination (dasatinib and quercetin), and other senolytics including flavonoid, fisetin, and BCL-xL inhibitors, illustrate the potential of senolytics to alleviate age-related dysfunction and diseases including wound healing. Translation into clinical applications requires parallel clinical trials across institutions to validate senotherapeutics as a vanguard for delaying, preventing, or treating age-related disorders and aesthetic aging.
Evaluating education innovations rapidly with build-measure-learn: Applying lean startup to health professions education
Cook, David A. , Bikkani, Abhishek, Carter, M. Jeannie Poterucha, Poterucha Carter, M Jeannie

Mayo Clinic

Medical Teacher | September 28, 2022 | Volume: 45 | Issue: 2 | Pages: 167-178

10.1080/0142159x.2022.2118038 | PMID 36170876 Get It

Clinical Applications and Controversies of Whole-Body MRI: AJR Expert Panel Narrative Review
Debs, Patrick , Omoumi, Patrick , Wessell, Daniel E. , Ahlawat, Shivani , Amini, Behrang , Lecouvet, Frederic E.

Mayo Clinic

American Journal of Roentgenology | September 28, 2022 | Volume: 220 | Issue: 4 | Pages: 463-475

10.2214/ajr.22.28229 | PMID 36169545 Get It

Feasibility of perioperative remote monitoring of patient‐generated health data in complex surgical oncology
Melstrom, Laleh G. , Zhou, Xiaoke , Kaiser, Andreas M. , Chan, Kevin , Lau, Clayton, Raoof, Mustafa , Zhumkhawala, Ali , Yuh, Bertram, Singh, Gagandeep , Fong, Yuman , Fong, Yuman , Melstrom, Laleh , Zhou, Xiaoke, Warner, Susanne G. , Sun, Virginia Chih-Yi

Mayo Clinic

Journal of Surgical Oncology | September 28, 2022 | Volume: 127 | Issue: 1 | Pages: 192-202

10.1002/jso.27106 | PMID 36169200 Get It

AbstractBackgroundThe feasibility of remote perioperative telemonitoring of patient‐generated physiologic health data and patient‐reported outcomes in a high risk complex general and urologic oncology surgery population is evaluated.MethodsComplex general surgical/urologic oncology patients wore a pedometer, completed ePROs (electronic patient‐reported outcome surveys) and record their vitals (weight, pulse, pulse oximetry, blood pressure, and temperature) via a telehealth app platform. Feasibility (% adherence) was assessed as the primary outcome measure.ResultsTwenty‐one patients with a median age 58 (32−82) years were included. The readmission rate was 33% and the incidence of ≥Grade 3a morbidity was 24%. Adherence to vital sign and ePRO measurements was 95% before surgery, 91% at discharge, and 82%, 68%, and 64% at postdischarge d2, 7, 14, and 30, respectively. There was significant worsening of mobility, self‐care and usual daily activity at postdischarge d2 compared to preoperative baseline (p < 0.05). Median daily preoperative steps taken by patients with <Grade 3a versus ≥Grade 3a postoperative morbidity was 6062 versus 4166 (p < 0.05). Of those interviewed, 87% (13/15) viewed vital sign devices as helpful in recovery.ConclusionsTelemonitoring is feasible in a general surgical and urologic oncology setting. Future studies will ascertain optimal patient selection, duration, and extent of perioperative monitoring.
Reevaluating Corticosteroid Classification Models in Patient Patch Testing
Chen, Joyce Y., Yiannias, James A. , Hall, Matthew R., Youssef, Molly J. , Drage, Lisa A., Davis, Mark D.P. , Yang, Yul W.

Mayo Clinic

JAMA Dermatology | September 28, 2022 | Volume: 158 | Issue: 11 | Pages: 1279

10.1001/jamadermatol.2022.3774 | PMID 36169950 Get It

Importance Individuals with allergic contact dermatitis to one topical corticosteroid may also react to other corticosteroids. Corticosteroid classification models have been proposed to predict such copositivity, recommend representative screening corticosteroids, and guide allergen avoidance. Objective To use patient data to determine copositivity patterns between corticosteroids and evaluate against previous corticosteroid classification models. Design, Setting, and Participants This qualitative study included a retrospective analysis of the Mayo Clinic Contact Dermatitis Group corticosteroid patch test data from 2010 to 2019. Among patients undergoing patch testing with the Mayo Clinic’s standard or steroid series who consented to research participation, 5637 patients were included in the analysis. Copositivity rates were determined between corticosteroids and analyzed by hierarchical clustering for comparison to previous classification models. Main Outcomes and Measures The frequency of patch test positivity to each of the analyzed corticosteroids was noted and compared with previously published patch test positivity rates. Copositivity rates between each pair of corticosteroids were determined, and overall copositivity patterns were analyzed and evaluated against known steroid classes. Results A total of 49 472 individual patches were applied to 5637 patients, testing 18 corticosteroids. Patch test positivity rates ranged between 0.3% and 4.7%. The fluocinonide positivity rate corresponded to the highest copositivity rate with other corticosteroids (mean [SD], 50.7% [26.1%]). Tixocortol-21-pivalate, 0.1%, and tixocortol-21-pivalate, 1%, positivity rates corresponded to the lowest copositivity rates (mean [SD], 4.1% [1.7%] and 3.6% [1.4%], respectively). Hierarchical clustering elucidated patterns that did not support previous corticosteroid classification models. Conclusions and Relevance In this qualitative study, copositivity rates were variable between corticosteroids, and overall patch test positivity for allergy to topical corticosteroids was rare. Previously published corticosteroid classifications are not supported by real patient-derived data and may not be accurate in predicting corticosteroid copositivity.
The Modernization of Clozapine
Leung, Jonathan G. , Frye, Mark A. , Singh, Balwinder , Cotes, Robert O. , Leung, Jonathan G , Singh, Balwinder , Cotes, Robert O , León, José de , McElroy, Susan L.

Mayo Clinic

Journal of Clinical Psychopharmacology | September 28, 2022 | Volume: 42 | Issue: 6 | Pages: 565-580

10.1097/jcp.0000000000001606 | PMID 36170148 Get It

Abstract Purpose Although clozapine was Food and Drug Administration (FDA) approved more than 3 decades ago, major barriers and gaps in knowledge continue to prevent its effective and safe use. We review modern-day problems encountered with clozapine in the United States (US). Methods Information surrounding current administrative, clinical, research, and technological gaps or barriers related to clozapine use in the US was reviewed. Findings The history of how clozapine became FDA approved likely contributes to gaps in knowledge. The frequency of safety warnings added to the FDA prescribing information may add to fears about clozapine, as evidence by numerous published survey studies. The clozapine Risk Evaluation and Mitigation Strategy (REMS) program has been modified several times in the last decade, causing access and safety issues for patients, which are discussed. Evidence may suggest that the FDA REMS requirements for hematologic monitoring are too cumbersome, and there may be ability to safely loosen requirements. The COVID-19 pandemic brought forth the ability for extended interval monitoring but also greater awareness of the clozapine-inflammation interaction. Newer guidelines published describe considerations in personalizing clozapine titration based on principles of ethnopsychopharmacology. Emerging technologies to support the use of clozapine are not widely available. Implications Clozapine is a unique life-saving drug but it is underused in the US, despite its established efficacy. The 2021 REMS changes led to significant difficulties for providers and patients. We highlight the importance of the clozapine-inflammation interaction, therapeutic drug monitoring, and the ability for individual care based on patient-specific factors. There is an urgent need for advancing technology used for clozapine monitoring, evaluating barriers created by REMS, and establishing consistent practices throughout the US.